Where neuroscience measurement meets regulatory strategy
Cerebral Innovations LLC is the company behind NeuroQuantix and FaceWise. Led by a clinical trial subject matter expert, we combine precision digital measurement technology with deep endpoint consulting expertise, serving global CNS clinical programs that demand more from their endpoints and their strategic advisors.
What drives our work
CNS clinical trials have a measurement problem. The assessment tools used in most neurological and psychiatric trials were developed decades ago. They rely on subjective observer ratings, operate at low resolution, and were never designed to detect the subtle treatment effects that modern therapeutics produce.
The consequence is real: clinical programs fail not because the therapeutic does not work, but because the endpoints cannot see that it works. This wastes years of development time, hundreds of millions in investment, and most importantly, delays treatments reaching patients who need them.
We started Cerebral Innovations to close this gap. By combining precision digital measurement technology with deep endpoint consulting expertise, we help sponsors build clinical programs where the measurement strategy is as sophisticated as the science behind their therapeutic.
Our Approach
What We Stand For
Measurement Precision
We believe that better measurement drives better clinical decisions. Every product and service we offer is built on the principle that precision in neurological assessment is not optional.
Regulatory Rigor
Clinical measurement exists within a global regulatory framework. We design everything we build with acceptance by FDA, EMA, and Health Canada as a core requirement, not an afterthought.
Early Engagement
The highest-impact decisions in clinical development happen in the earliest stages. We engage early because correcting measurement strategy mid-program costs orders of magnitude more than getting it right from the start.
Scientific Integrity
We recommend what works, not what sells. Our consulting advice is grounded in published evidence, regulatory precedent, and firsthand experience with what survives the scrutiny of regulatory review.
Meet the founder
David McLaughlin
Founder & CEO
Cerebral Innovations LLC
David McLaughlin is a clinical trial subject matter expert with hands-on experience across 40+ CNS clinical trials spanning essential tremor, Parkinson disease, Alzheimer disease, Huntington disease, ALS, epilepsy, psychiatric disorders, and rare neurological conditions. His trial experience covers Phases 1 through 4 across FDA, EMA, and Health Canada regulatory jurisdictions.
He founded Cerebral Innovations to address a persistent gap in clinical development: the mismatch between modern therapeutics and the decades-old measurement tools used to evaluate them. His work combines precision digital biomarker technology with strategic consulting for sponsors designing endpoint strategies for global regulatory submissions.
David is a published co-author of a scoping review in Movement Disorders Clinical Practice that mapped the evidence base across 120 studies of digitized spiral analysis. That review identified the standardization gaps that NeuroQuantix is designed to address.
Key Opinion Leader network
Clinical development decisions are stronger when informed by the physicians and researchers who treat these conditions every day. Cerebral Innovations maintains relationships with Key Opinion Leaders across neurology, movement disorders, and CNS clinical development.
Our KOL network, with connections across the Movement Disorder Society and leading academic centers, accelerates protocol design, site selection, endpoint validation, and regulatory strategy, giving your program access to the domain expertise that shapes how clinical evidence is interpreted by regulators and the medical community.
Movement Disorders
ET, PD, dystonia, DBS programming
Neurodegenerative Disease
AD, MCI, HD, PSP, MSA
Clinical Trial Design
Protocol, endpoints, statistics
Regulatory Science
FDA and EMA advisory experience
Digital Biomarkers
Sensor validation, COA development
Rare Disease
Gene therapy, natural history studies
Publications & Research
Movement Disorders Clinical Practice · 2025; 12(11): 1742–1755
Clinical Applications and Measurement Properties of the Digitized Archimedes Spiral Drawing Test
Wang S, Schwirtlich T, McLaughlin D, Beestrum M, Heinemann AW
Scoping review of 120 studies mapping the evidence base for digitized spiral analysis as a clinical outcome measurement instrument. The review identifies standardization gaps that NeuroQuantix is designed to address.
Frequently Asked Questions
Who is behind Cerebral Innovations?
Cerebral Innovations LLC was founded by David McLaughlin, a clinical trial subject matter expert with hands-on experience across 40+ CNS clinical trials spanning essential tremor, Parkinson disease, Alzheimer disease, Huntington disease, ALS, epilepsy, and rare neurological conditions. His trial experience covers Phases 1 through 4 across five global regulatory jurisdictions.
What products does Cerebral Innovations offer?
Two precision digital neuroscience assessment platforms. NeuroQuantix extracts 397 kinematic metrics from a brief spiral drawing assessment for movement disorder trials. FaceWise measures sleep-dependent memory consolidation through AI-administered overnight delayed recall for Alzheimer and cognitive decline trials.
Where is Cerebral Innovations located?
Cerebral Innovations LLC is headquartered in St. Petersburg, Florida. The company serves pharmaceutical sponsors, biotechnology companies, CROs, and academic research institutions worldwide across five regulatory jurisdictions.
What is Cerebral Innovations' approach to digital endpoints?
Evidence-based and regulatory-focused. Every product is grounded in published peer-reviewed literature with full citation provenance. Diagnostic rules use deterministic logic rather than opaque machine learning. The approach starts with the clinical question and works backward through regulatory requirements.
What consulting services does Cerebral Innovations provide?
Endpoint consulting, central rater committee design and implementation, regulatory strategy for digital health technologies and COA/DDT qualification, and general CNS clinical consulting. All services draw on direct experience across 40+ CNS clinical programs.
Let us show you what precision looks like
Whether you are planning a first-in-human study or optimizing a Phase 3 endpoint strategy, we would welcome the conversation.
Get in Touch